Focus on Lipids Care

Back to articles

New studies question role of HDL in cardiac risk

KEY POINT

The number of HDL particles (HDL-P) may be a better marker of residual risk for cardiovascular events in patients treated with rosuvastatin (Crestor—AstraZeneca) than HDL-cholesterol (HDL-C) or apolipoprotein A-I (apoA-I).

SOURCES

Mora S et al. High-density lipoprotein cholesterol, size, particle number, and residual vascular risk after potent statin therapy. Circulation. 2013;128:1189–97.

Nicholls SJ et al. Is it time for HDL to change its tune [editorial]? Circulation. 2013;128:1175–6. http://circ.ahajournals.org/content/128/11/1175

Acharjee et al. Low levels of high density lipoprotein cholesterol and increased risk of cardiovascular events in stable ischemic heart disease patients: a post hoc analysis from the COURAGE trial. J Am Coll Cardiol. 2013; 62:1826–33.

van de Woestijine AP et al. Low high-density lipoprotein cholesterol is not a risk factor for recurrent vascular events in patients with vascular disease on intensive lipid-lowering medication. J Am Coll Cardiol. 2013;62:1834–47.